PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34193682-6 2021 Additionally, intra-mPFC infusion of dihydro-beta-erythroidine, a selective alpha4beta2 nAChR antagonist, or methyllycaconitine, a selective alpha7 nAChR antagonist, significantly suppressed the nicotine-induced object recognition memory enhancement. Dihydro-beta-Erythroidine 37-62 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 88-93 32747456-6 2020 We then performed whole-cell patch-clamp electrophysiology and observed farnesene-induced inward currents in ventral tegmental area (VTA) putative dopamine neurons that were blocked by the nAChR antagonist, DhbetaE. Dihydro-beta-Erythroidine 207-214 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 189-194 35231469-4 2022 Nicotine-induced depression in sensory stimulation-evoked MLI-PC synaptic transmission was abolished by either a non-selective nAChR blocker, hexamethonium, or the alpha7-nAChR antagonist methyllycaconitine (MLA), but not the selective alpha4beta2-nAChR antagonist dihydro-beta-erythroidine. Dihydro-beta-Erythroidine 265-290 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 127-132 32092237-0 2020 Unexpected loss of sensitivity to the nicotinic acetylcholine receptor antagonist activity of mecamylamine and dihydro-beta-erythroidine in nicotine-tolerant mice. Dihydro-beta-Erythroidine 111-136 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 38-70 27238974-7 2016 Mecamylamine and the alpha4beta2 nAChR antagonist dihydro-beta-erythroidine, but not the alpha7 antagonist methyllycaconitine, antagonized the hypothermic effects of nicotine. Dihydro-beta-Erythroidine 50-75 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 33-38 31881170-4 2020 Furthermore, chronic treatment with the beta2-selective nAChR competitive antagonist dihydro-beta-erythroidine (DHbetaE) in mice fed a high-fat diet suppresses weight gain. Dihydro-beta-Erythroidine 85-110 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 56-61 31881170-4 2020 Furthermore, chronic treatment with the beta2-selective nAChR competitive antagonist dihydro-beta-erythroidine (DHbetaE) in mice fed a high-fat diet suppresses weight gain. Dihydro-beta-Erythroidine 112-119 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 56-61 29910731-6 2018 These effects were blocked by pretreatments with the alpha6*nAChR antagonists alpha-conotoxin MII and alpha-conotoxin PIA, as well as by the alpha4beta2nAChR antagonist dihydro-beta-erythroidine (DHbetaE) in both mouse and human DA neurons. Dihydro-beta-Erythroidine 196-203 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 53-65 23325242-7 2013 Hence, LTP was prevented by alpha7 nAChR antagonists dihydro-beta-erythroidine and methyllycaconitine (MLA) and was absent in alpha7(-/-) mice. Dihydro-beta-Erythroidine 53-78 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 28-40 26256075-3 2015 Among subtype-selective nAChR antagonists, the beta2-selective antagonist dihydrobetaerythroidine and alpha7 antagonist methyllycaconitine (MLA), but not MLA alone prevent behavioral sensitization to cocaine. Dihydro-beta-Erythroidine 74-97 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 24-29 24800895-9 2014 The beta2-subunit selective nAChR antagonist dihydro-beta-erythroidine (DHbetaE; up to 10 mg/kg) antagonized hypothermic effects but less effectively so than mecamylamine. Dihydro-beta-Erythroidine 45-70 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 28-33 24800895-9 2014 The beta2-subunit selective nAChR antagonist dihydro-beta-erythroidine (DHbetaE; up to 10 mg/kg) antagonized hypothermic effects but less effectively so than mecamylamine. Dihydro-beta-Erythroidine 72-79 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 28-33 23811311-2 2013 We have analyzed the nicotinic component of the EPSC which is blocked by dihydro-beta-erythroidine (DHbetaE) with the dual objective of identifying the nAChR subunits involved and of understanding the kinetics of the response. Dihydro-beta-Erythroidine 73-98 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 152-157 23811311-2 2013 We have analyzed the nicotinic component of the EPSC which is blocked by dihydro-beta-erythroidine (DHbetaE) with the dual objective of identifying the nAChR subunits involved and of understanding the kinetics of the response. Dihydro-beta-Erythroidine 100-107 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 152-157 23811311-3 2013 The sensitivity to DHbetaE of the peak of the EPSC was differentially affected by genetic deletion of three specific nAChR subunits: alpha2, beta2 and beta4. Dihydro-beta-Erythroidine 19-26 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 117-122 22741175-2 2012 The present study examined the efficacy of nAChR ligands with different pharmacological profiles such as cytisine, lobeline and dihydro-beta-erythroidine (DHbetaE) to modulate chronic nicotine-induced increase in ethanol intake by C57BL/6J mice, using a two-bottle choice procedure. Dihydro-beta-Erythroidine 155-162 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 43-48 23272676-5 2012 RESULTS: GABAergic interneurons in the CA1 subregion of the hippocampus expressed functional alpha7beta2-nAChRs, which were characterized by relatively slow whole-cell current kinetics, pharmacological sensitivity to dihydro-beta-erythroidine (DHbetaE), a nAChR beta2* subunit selective blocker, and alpha7 and beta2 subunit interaction using immunoprecipitation assay. Dihydro-beta-Erythroidine 217-242 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 105-110 23272676-5 2012 RESULTS: GABAergic interneurons in the CA1 subregion of the hippocampus expressed functional alpha7beta2-nAChRs, which were characterized by relatively slow whole-cell current kinetics, pharmacological sensitivity to dihydro-beta-erythroidine (DHbetaE), a nAChR beta2* subunit selective blocker, and alpha7 and beta2 subunit interaction using immunoprecipitation assay. Dihydro-beta-Erythroidine 244-251 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 105-110 22036617-9 2011 Moreover, nicotine-induced analgesia was suppressed by dihydro-beta-erythroidine (DHbetaE; an antagonist for the alpha4beta2 nAChR) or methyllycaconitine (MLA; an antagonist for the alpha7 nAChR). Dihydro-beta-Erythroidine 55-80 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 125-130 22357798-9 2012 Immunolabel was blocked by intracortical microinjection of the nAChR antagonist dihydro-beta-erythroidine, but not methyllycaconitine, implicating alpha4beta2*, but not alpha7, nAChRs. Dihydro-beta-Erythroidine 80-105 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 63-68 22036617-9 2011 Moreover, nicotine-induced analgesia was suppressed by dihydro-beta-erythroidine (DHbetaE; an antagonist for the alpha4beta2 nAChR) or methyllycaconitine (MLA; an antagonist for the alpha7 nAChR). Dihydro-beta-Erythroidine 82-89 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 125-130 21487659-5 2011 The role of beta2* nAChRs was confirmed by results showing: (1) reversal of sazetidine"s antidepressant-like effects in the forced swim test by nAChR antagonists mecamylamine and dihydro-beta-erythroidine; (2) absence of sazetidine"s effect in mice lacking the beta2 subunit of the nAChR; and (3) a high correspondence between behaviorally active doses of sazetidine and beta2* receptor occupancy. Dihydro-beta-Erythroidine 179-204 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 19-24 16934231-6 2006 DHbetaE (500 ng), a alpha(4)beta(2) selective nAChR antagonist, virtually abolished RJR-2403-induced attenuation of Delta(9)-THC ataxia. Dihydro-beta-Erythroidine 0-7 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 46-51 19176801-7 2009 Slow whole-cell current kinetics, sensitivity to DHbetaE, and specific antagonism by oligomeric Abeta(1-42) also are characteristics of heteromeric alpha7beta2-nAChRs, but not of homomeric alpha7-nAChRs, heterologously expressed in Xenopus oocytes. Dihydro-beta-Erythroidine 49-56 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 148-154 17584502-8 2008 The high affinity nAChR antagonist dihydro-beta-erythroidine (DH beta E; 3mg/kg) was administered prior to training or testing to precipitate withdrawal in chronic nicotine-treated C57BL/6 mice. Dihydro-beta-Erythroidine 35-60 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 18-23 17584502-8 2008 The high affinity nAChR antagonist dihydro-beta-erythroidine (DH beta E; 3mg/kg) was administered prior to training or testing to precipitate withdrawal in chronic nicotine-treated C57BL/6 mice. Dihydro-beta-Erythroidine 62-71 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 18-23 21167848-6 2011 The high-affinity nAChR antagonist Dihydro-beta-erythroidine hydrobromide (DhbetaE) blocked the effects of nicotine on MK-801-induced deficits while the alpha7 nAChR antagonist methyllycaconitine citrate salt hydrate (MLA) did not. Dihydro-beta-Erythroidine 75-82 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 18-23 17716785-8 2008 The pro-oxidative effect induced by AMPH and MDMA showed a strong dependence on calcium (extracellular and from internal stores) and also was inhibited by nicotinic receptor (nAChR) antagonists dihydro-beta-erythroidine, methyllycaconitine (MLA) and alpha-bungarotoxin. Dihydro-beta-Erythroidine 194-219 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 175-180 18184794-7 2008 The alpha4*-selective nAChR antagonist dihydro-beta-erythroidine produced opposite effects and blocked the nicotinic responses. Dihydro-beta-Erythroidine 39-64 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 22-27 17016705-8 2006 The competitive nAChR antagonist dihydro-beta-erythroidine, but not the blood-brain barrier impermeant antagonist hexamethonium, also decreased immobility in the TST. Dihydro-beta-Erythroidine 33-58 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 16-21 16934231-9 2006 Additionally, ICB treatment with DHbetaE virtually abolished nicotine-induced attenuation of Delta(9)-THC ataxia that suggested alpha(4)beta(2) as the primary cerebellar nAChR subtype. Dihydro-beta-Erythroidine 33-40 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 170-175 16416156-7 2006 RESULTS: We have demonstrated that a pretreatment with the alpha4beta2 subunit of the nicotinic acetylcholine receptor (nAChR) antagonist dihydro-beta-erythroidine (2.0 mg/kg, s.c.) blocked nicotine (0.5 mg/kg, s.c.) CPP in wild-type mice (C57BL/6 mice). Dihydro-beta-Erythroidine 138-163 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 86-118 16416156-7 2006 RESULTS: We have demonstrated that a pretreatment with the alpha4beta2 subunit of the nicotinic acetylcholine receptor (nAChR) antagonist dihydro-beta-erythroidine (2.0 mg/kg, s.c.) blocked nicotine (0.5 mg/kg, s.c.) CPP in wild-type mice (C57BL/6 mice). Dihydro-beta-Erythroidine 138-163 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 120-125 15569257-5 2004 Based on agonist profiles and sensitivity to the antagonist dihydro-beta-erythroidine (DHbetaE), the predominant alpha4beta2 nAchR expressed in the mmalpha4beta2 cells exhibits a pharmacology that most resembles the DHbetaE-sensitive component of 86Rb+ efflux from mouse brain synaptosomes. Dihydro-beta-Erythroidine 60-85 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 125-130 15569257-5 2004 Based on agonist profiles and sensitivity to the antagonist dihydro-beta-erythroidine (DHbetaE), the predominant alpha4beta2 nAchR expressed in the mmalpha4beta2 cells exhibits a pharmacology that most resembles the DHbetaE-sensitive component of 86Rb+ efflux from mouse brain synaptosomes. Dihydro-beta-Erythroidine 87-94 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 125-130 15569257-5 2004 Based on agonist profiles and sensitivity to the antagonist dihydro-beta-erythroidine (DHbetaE), the predominant alpha4beta2 nAchR expressed in the mmalpha4beta2 cells exhibits a pharmacology that most resembles the DHbetaE-sensitive component of 86Rb+ efflux from mouse brain synaptosomes. Dihydro-beta-Erythroidine 216-223 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 125-130 9922707-6 1999 The N-nAChR are activated by nicotine and choline, and RAMIC are antagonized by methyllycaconitine and dihydro-beta-erythroidine. Dihydro-beta-Erythroidine 103-128 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 6-11